Although the potential predictive power of PD-L1 expression for the clinical benefit of anti-PD-1 therapy remains controversial for advanced melanoma patients10,11, higher TMB has been correlated with a superior clinical response12,13, improved survival14,15, and durable benefit12,16 in advanced melanomas. This evidence concerns the gene CD274 and melanoma.